CMR Naviscan

Executive Summary

CMR Naviscan is a San Diego-based medical technology company dedicated to improving breast cancer detection through its LumaGEM Molecular Breast Imaging (MBI) system. The system addresses a critical gap in screening: women with dense breast tissue, for whom mammography alone has reduced sensitivity. By using a dedicated gamma camera and a targeted radiotracer, LumaGEM provides high-resolution functional imaging, significantly increasing cancer detection rates while reducing benign biopsies. The technology has been clinically validated to lower the cost per cancer detected compared to standard mammography, offering an economically attractive adjunct for breast imaging centers. With a focus on the underserved dense breast population, CMR Naviscan is positioned to capture a growing segment of the breast imaging market as awareness and guidelines increasingly recommend supplemental screening. The company operates in a competitive landscape that includes other molecular imaging modalities such as breast MRI and automated breast ultrasound, yet LumaGEM’s lower cost, ease of use, and high specificity give it a distinct advantage. CMR Naviscan has established commercial presence in the U.S. and select international markets, but widespread adoption remains limited. Key to future growth will be expanding clinical evidence, gaining inclusion in professional guidelines, and securing reimbursement parity with alternative modalities. The company’s private status and lack of disclosed funding suggest it may be approaching a strategic inflection point, potentially seeking partnerships or capital to scale commercialization and further penetrate the $1B+ global breast cancer diagnostics market.

Upcoming Catalysts (preview)

• Q4 2026Publication of pivotal clinical study comparing LumaGEM to breast MRI in dense breast patients60% success
• Q2 2027Strategic partnership or distribution agreement with a major imaging OEM for U.S. expansion40% success
• Q1 2027Series C funding round to support commercial scale-up and regulatory approvals in Europe50% success